The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations
- Citation:
- Blood vol 130 (Suppl 1) 2580
- Meeting Instance:
- ASH 2017
- Year:
- 2017
- Type:
- Abstract
- Sub type:
- Poster Discussion
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3367
- Pharmas:
- Novartis Pharma
- Grants:
- U10CA180821, U10CA180882, U10CA31946, U10CA180791, U10CA180820, U10CA180888, U24CA196171, U10CA180863, (CCSRI) 704970;
- Corr. Author:
- Authors:
- Richard M. Stone Sumithra Mandrekar Ben L Sanford Susan Geyer Clara D. Bloomfield Konstanze Dohner Christian Thiede Guido Marcucci Francesco Lo-Coco Rebecca B. Klisovic Andrew Wei Jorge Sierra Miguel A. Sanz Joseph M. Brandwein Theo de Witte Dietger Niederwieser Frederick R. Appelbaum Bruno C. Medeiros Martin S. Tallman Jurgen Krauter *Richard F. Schlenk Arnold Ganser Hubert Serve Gerhard Ehninger Sergio Amadori Hartmut Dohner Richard A. Larson
- Networks:
- CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-OH007
- Study
- CALGB-10603
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: